Cancer Pain

Abstract

Cancer pain is a type of pain caused by a malignant tumor invading or compressing tissue, or by the treatments used against it. It is among the most feared consequences of cancer and one of the most common, yet it remains widely undertreated even where effective analgesics exist. This article develops cancer pain as a cognitive problem as much as a clinical one: why a private, subjective symptom can only be managed once it is made measurable, how the same nociceptive signal is amplified or dampened by attention, mood, and appraisal, why the standard measure of undertreatment is arithmetic on self-report, and why psychological methods belong alongside the analgesic ladder rather than beneath it.

Keywords: cancer pain, pain assessment, Brief Pain Inventory, pain catastrophizing, undertreatment

Pain is what patients fear most about a cancer diagnosis, and for good reason: it is common, it worsens as disease advances, and its presence colors mood, sleep, function, and the will to continue treatment. But cancer pain has a peculiar epistemic status that makes it a subject for cognitive psychology and not oncology alone. It is invisible. No scan or assay measures a patient's pain; the only instrument is the patient's report, filtered through memory, mood, and expectation before it is ever spoken. A symptom that exists only as reported experience must be elicited, quantified, and acted upon through the machinery of self-report and appraisal, and every failure of that machinery — a report not sought, a scale not understood, a fear that inflates or a stoicism that conceals — becomes a failure of treatment. That is why cancer pain, for all its physical cause, is at its core a problem in the psychology of measurement, attention, and belief.

What Cancer Pain Is

Cancer pain is pain that arises from a malignancy or from the interventions used to treat it, and the distinction between those two sources organizes the whole field. Tumor-related pain comes from a cancer invading or compressing bone, nerve, viscera, or soft tissue; treatment-related pain follows surgery, chemotherapy, or radiation, and can outlast the disease itself. Mechanistically it spans the same categories as pain in general, being in part nociceptive, arising from ongoing tissue damage, and in part neuropathic, arising from damage to the nervous system, with most patients experiencing a mixture whose proportions shape which analgesics will help (Portenoy, 2011). A large international survey of cancer pain established that it is rarely a single symptom: patients typically report several distinct pains at once, of different mechanisms and sites, each requiring separate characterization, which is why assessment cannot stop at a single number (Caraceni & Portenoy, 1999).

The revised International Association for the Study of Pain definition frames pain as an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage — a definition that deliberately makes the emotional dimension constitutive rather than secondary (Raja et al., 2020). For cancer pain this framing is not academic. It means that the dread attached to a pain understood as a sign of advancing disease is part of the pain, not a reaction layered on top of it, and it licenses the cognitive-psychological treatment of cancer pain as a legitimate clinical target rather than a soft adjunct.

However it is classified, cancer pain is common. A systematic review and meta-analysis found pain in roughly half of patients across all stages, rising to about two-thirds of those with advanced, metastatic, or terminal disease, and still present in nearly two-fifths of patients after curative treatment; of those in pain, more than a third rated it as moderate to severe (van den Beuken-van Everdingen et al., 2016). Superimposed on this persistent pain, most patients also suffer transient flares — breakthrough pain — that erupt against an otherwise controlled background and demand their own rapid treatment (Mercadante & Portenoy, 2021). The scale of the problem, and the fact that so much of it is moderate or severe, is the backdrop against which the failure to treat it adequately becomes so striking. Figure 1 sets out how pain prevalence changes across the disease course.

Figure 1

Prevalence of Pain Across the Cancer Disease Course

Assessing Cancer Pain

The central practical fact about cancer pain is that it cannot be seen, only reported, and this makes assessment the hinge on which everything else turns. A pain that is not asked about, or that is reported through a scale the patient misunderstands, is a pain that cannot be treated. The response of the field has been to build validated self-report instruments that make the invisible symptom measurable and comparable across patients, clinicians, and studies. The most widely used is the Brief Pain Inventory, which asks patients to rate their pain at its worst, least, and average over the past day, and right now, on a zero-to-ten scale, and separately to rate how much pain has interfered with mood, activity, sleep, work, relationships, and enjoyment of life (Cleeland & Ryan, 1994). The instrument's crucial design insight is that pain has two dimensions that do not reduce to each other — a severity dimension and an interference dimension — so that two patients with the same intensity may differ greatly in how much that intensity disrupts their lives. The first demonstration lets these two dimensions be set independently, showing how the Brief Pain Inventory separates how much a pain hurts from how much it costs.

Making pain measurable exposed how badly it was being treated. A landmark study of outpatients with metastatic cancer found that a large fraction were in pain severe enough to impair function yet were receiving analgesics inadequate to their reported severity, and that the mismatch was worse for the elderly, for women, and for minority patients (Cleeland et al., 1994). The finding was possible only because pain had been quantified: undertreatment is not a feeling but a discrepancy between two measured quantities, the strength of the analgesic prescribed and the severity of the pain reported. That discrepancy was later formalized as the Pain Management Index, which subtracts the reported pain level from the potency level of the strongest analgesic given, so that a negative value flags a patient whose treatment is weaker than their pain. A systematic review using this index across dozens of studies found that a large minority of cancer patients — on the order of two in five — were undertreated by this measure, a figure that had barely improved over decades (Deandrea et al., 2008). The persistence of that gap, in an era of effective and inexpensive opioids, points past pharmacology to the cognitive and attitudinal barriers, in patients and clinicians alike, that keep pain unspoken and unmedicated.

Assessment is complicated further by the fact that self-report is not a transparent window onto sensation. What a patient reports is shaped by mood, by fear of what the pain signifies, by beliefs about addiction and about being a good patient, and by the reconstruction that memory imposes on any pain recalled rather than rated in the moment. A thorough review of psychosocial factors in cancer pain documented how depression, anxiety, and coping style each color reported pain and its impact, so that the number a patient gives is a joint product of nociception and psychology, never the former alone (Zaza & Baine, 2002). This is not a reason to distrust self-report — it remains the only valid measure — but a reason to interpret it as the psychological quantity it is.

The Psychology of Cancer Pain

That the same injury can hurt more or less depending on the state of the mind is the oldest insight of pain science, and it received its first mechanistic form in the gate-control theory, which proposed that signals descending from the brain could open or close a spinal gate and so modulate the pain signals ascending from the body (Melzack & Wall, 1965). Whatever the fate of its specific neural claims, gate control established the principle that pain is not a fixed readout of tissue damage but a modulated signal, and it made room for attention, emotion, and expectation as genuine causes of how much a pain hurts. Modern neuroimaging has confirmed the principle in detail: the perceived intensity of an identical noxious stimulus rises and falls with attention, mood, and belief, through identifiable circuits that gate the nociceptive signal on its way to awareness (Bushnell et al., 2013). The second demonstration makes this modulation tangible, holding a nociceptive input fixed while attention and appraisal are varied, so the gap between the signal and the suffering can be seen.

Attention is the first modulator. Pain is, functionally, a demand for attention: it interrupts whatever the mind is doing and pulls processing toward the body, an interruptive function that is adaptive for acute injury but corrosive when pain is chronic and its message is already known (Eccleston & Crombez, 1999). Because attention is limited, a pain that captures it leaves less for everything else, which is why distraction can genuinely reduce perceived pain and why a pain that cannot be ignored is so much worse than one that can. For the cancer patient, the involuntary vigilance toward a pain that signifies disease is both a source of suffering and a target for intervention.

Appraisal is the second modulator, and its best-studied form is pain catastrophizing: a magnified, ruminative, and helpless orientation toward actual or anticipated pain. The construct was operationalized in the Pain Catastrophizing Scale, which distinguishes rumination, magnification, and helplessness, and which predicts pain intensity, emotional distress, and functional interference across pain conditions (Sullivan et al., 1995). In cancer specifically, catastrophizing predicts worse pain and greater interference over and above the extent of disease, so that two patients with the same tumor and the same nociceptive input can suffer very differently depending on how each interprets the sensation (Syrjala et al., 2014). Catastrophizing is not weakness or exaggeration; it is a measurable cognitive style that amplifies the pain signal, and because it is cognitive it is modifiable, which is what makes psychological treatment of cancer pain more than palliative hand-holding.

Managing Cancer Pain

The pharmacological backbone of cancer pain management is the analgesic ladder introduced by the World Health Organization, which prescribes non-opioid analgesics for mild pain, adds a weak opioid for moderate pain, and moves to a strong opioid for severe pain, with adjuvants added at any step. A validation study following patients treated by this method found that it achieved satisfactory relief in the large majority, establishing a simple, teachable framework that remains the foundation of practice (Ventafridda et al., 1987). The ladder's enduring value is less any specific drug than its logic of matching analgesic strength to reported pain severity — the same matching whose failure the Pain Management Index measures. Contemporary opioid practice refines this with evidence-based recommendations on choice, titration, rotation, and the management of side effects, so that the strong-opioid step is executed well rather than merely reached (Caraceni et al., 2012). Table 1 sets out the ladder and the reported pain severity each step is meant to match.

Pharmacology is necessary but not sufficient, because the pain it treats is modulated by the cognitive and emotional factors of the previous section, and those are reached by psychological rather than chemical means. A body of controlled work supports psychological and behavioral approaches — education about pain and its treatment, training in coping skills and relaxation, cognitive restructuring of catastrophic beliefs, and attention-management techniques — as effective adjuncts that reduce pain and its interference beyond what analgesics achieve alone (Syrjala et al., 2014). Modern guidelines integrate these strands, pairing the analgesic ladder with psychosocial support, attention to the whole symptom cluster, and individualized titration, and framing good pain control as a coordinated cognitive, emotional, and pharmacological effort rather than a prescription (Fallon et al., 2018; Scarborough & Smith, 2018). The persistence of undertreatment despite this consensus is itself a psychological phenomenon: it reflects patients' fears of opioids and reluctance to report pain, and clinicians' misjudgment of severity, as much as any gap in the pharmacopeia (Deandrea et al., 2008).

Worked Example

Consider the Pain Management Index, the measure the second half of this article keeps returning to, and use it to see why undertreatment is a matter of arithmetic on self-report. The index scores reported pain on a four-level scale — 0 for none, 1 for mild pain (rated 1 to 4 out of 10), 2 for moderate (5 to 6), and 3 for severe (7 to 10) — and scores the strongest analgesic given on a matching four-level scale — 0 for none, 1 for a non-opioid, 2 for a weak opioid, and 3 for a strong opioid. The index is their difference, PMI = analgesic level − pain level, and a negative value marks a patient whose treatment is weaker than their reported pain, the operational definition of undertreatment (Deandrea et al., 2008).

Take a patient who rates her worst pain at 8 out of 10, which places her at pain level 3, but who is receiving only a non-opioid anti-inflammatory, potency level 1. Her index is 1 − 3 = −2: strongly negative, and so undertreated. The arithmetic captures precisely what the Cleeland et al. (1994) survey found — a severe pain met with a mild analgesic. Now move her up the ladder to a strong opioid, potency level 3, matched to her severe pain. Her index becomes 3 − 3 = 0: no longer negative, and so counted as adequately treated. Note that adequacy here is defined as parity, an index of zero or above; the measure asks only whether the analgesic reaches the level of the pain, not whether the pain is abolished.

The example makes the undertreatment statistic concrete. When a review reports that around two in five cancer patients have a negative Pain Management Index, it is reporting that for two in five patients the difference of these two small integers comes out below zero — that the strength of the drug, scored 0 to 3, falls short of the severity of the pain, scored 0 to 3 (Deandrea et al., 2008). The crudeness of the scale is the point: undertreatment on this scale is not a subtle failure of fine titration but a gross mismatch, a severe pain treated as though it were mild, and that it remains so common is what turns a solvable pharmacological problem into a stubborn cognitive and attitudinal one.

Discussion

The study of cancer pain traces a movement from an invisible symptom to a measured one, and from a purely pharmacological target to a cognitive one, with each step enabled by the last. Gate-control theory made it thinkable that the mind modulates pain; self-report instruments like the Brief Pain Inventory made that modulation, and the pain itself, measurable; and measurement in turn made undertreatment visible as a discrepancy rather than a complaint (Melzack & Wall, 1965; Cleeland & Ryan, 1994; Cleeland et al., 1994). The arc is characteristic of cognitive psychology's contribution to medicine: not to replace the biological account but to supply the tools — scales, models, and experiments — that turn a subjective state into something that can be studied and improved.

What the cognitive lens adds to the clinical picture is an explanation of the two facts that most define cancer pain: that it is so often undertreated, and that the same disease causes such different suffering in different people. Undertreatment persists because the pathway from nociception to treatment runs entirely through report and appraisal, and every psychological barrier along that pathway — a patient's fear of opioids or reluctance to seem weak, a clinician's underestimation of another's pain — subtracts from the analgesia delivered (Deandrea et al., 2008; Zaza & Baine, 2002). And suffering varies because attention and appraisal genuinely modulate the pain signal, so that catastrophizing inflates it and distraction and reappraisal can damp it (Sullivan et al., 1995; Bushnell et al., 2013). Both facts point to the same conclusion: that treating cancer pain well requires treating the mind that reports and interprets it, not only the body that generates it.

Current Directions

The frontier of cancer pain has shifted with the disease it accompanies. As treatment turns more cancers into survivable and even chronic conditions, the problem of pain in survivors — long after the tumor is gone, from surgery, chemotherapy-induced neuropathy, and radiation — has become a field of its own, and clinical guidelines now address the survivor's persistent pain as distinct from the pain of active disease (Paice et al., 2016). At the same time, the opioid crisis has reshaped the context in which cancer pain is treated, forcing a re-examination of how to relieve severe pain without contributing to harm, and modern reviews stress balancing effective analgesia against the risks of long-term opioid use, especially in survivors with years of life ahead (Scarborough & Smith, 2018). Breakthrough pain, the transient flare against a controlled background, remains an active problem precisely because its rapid, variable time course resists the standing regimen, and recent work characterizes it as a chameleonic phenomenon demanding rapid-onset, individualized treatment (Mercadante & Portenoy, 2021). Across all of these, the enduring open question is the one this article began with: how to close the gap between the pain patients feel and the relief they receive, a gap that has proven far more resistant to the availability of good drugs than to the availability of good measurement, and whose stubbornness keeps the cognitive psychology of report, belief, and attention at the center of a problem that looks, at first glance, purely physical.

Common Misconceptions

Cancer pain is an unavoidable part of having cancer.

The great majority of cancer pain can be controlled with existing treatments applied according to the analgesic ladder; the fact that a large minority of patients remain undertreated reflects barriers of reporting, belief, and prescribing rather than any intractability of the pain itself (Ventafridda et al., 1987; Deandrea et al., 2008).

A pain rating is a direct readout of tissue damage.

The perceived intensity of an identical nociceptive signal rises and falls with attention, mood, and appraisal; a reported pain score is a joint product of nociception and psychology, which is why two patients with the same disease can suffer very differently (Bushnell et al., 2013; Sullivan et al., 1995).

Psychological treatment of pain implies the pain is not real.

Because pain is by definition a sensory and emotional experience, cognitive and behavioral methods act on genuine determinants of how much a real pain hurts; they are effective adjuncts to analgesics, not a substitute for them or a denial of the pain's physical cause (Raja et al., 2020; Syrjala et al., 2014).

Glossary

Analgesic ladder.

The World Health Organization's stepwise scheme for cancer pain, moving from non-opioid to weak opioid to strong opioid as reported pain severity rises, with adjuvants added at any step.

Appraisal.

The cognitive evaluation of a sensation's meaning and threat; in pain, the interpretation of what a sensation signifies, which modulates how intensely an identical nociceptive signal is felt.

Breakthrough pain.

A transient flare of severe pain erupting against a background of otherwise controlled persistent pain; common in cancer and requiring its own rapid-onset treatment.

Brief Pain Inventory.

A validated self-report instrument that rates pain severity (worst, least, average, and current) and, separately, the interference of pain with mood, activity, sleep, work, relationships, and enjoyment of life.

Cancer pain.

Pain caused by a malignant tumor invading or compressing tissue, or by the surgery, chemotherapy, or radiation used to treat it; often a mixture of nociceptive and neuropathic mechanisms.

Gate-control theory.

The proposal that neural signals descending from the brain can open or close a spinal gate and so modulate ascending pain signals, establishing that pain is a modulated signal rather than a fixed readout of injury.

Interference.

The extent to which pain disrupts function and quality of life, measured separately from severity, so that equally intense pains may differ greatly in their cost to a patient's life.

Neuropathic pain.

Pain arising from damage to or disease of the nervous system itself, as when a tumor or its treatment injures a nerve; often described as burning or shooting and responsive to different drugs than nociceptive pain.

Nociceptive pain.

Pain arising from ongoing tissue damage detected by sensory receptors, as when a tumor invades bone or soft tissue; the category the analgesic ladder was chiefly designed to treat.

Opioid.

A class of analgesic drugs acting on opioid receptors, divided in the analgesic ladder into weak opioids for moderate pain and strong opioids for severe pain; the mainstay of pharmacological cancer pain relief.

Pain catastrophizing.

A magnified, ruminative, and helpless orientation toward actual or anticipated pain, measured by the Pain Catastrophizing Scale and predicting greater pain intensity, distress, and interference.

Pain Management Index.

A measure of treatment adequacy that subtracts the reported pain level (0-3) from the potency level of the strongest analgesic given (0-3); a negative value indicates undertreatment.

Self-report.

A patient's own account of their pain, the only valid measure of a private experience, and therefore the quantity that assessment instruments are built to elicit as faithfully as possible.

Undertreatment.

The provision of analgesia weaker than a patient's reported pain severity, operationalized as a negative Pain Management Index and found in a large minority of cancer patients.

Key Researchers

Augusto Caraceni (contemporary). Palliative-care physician at the Istituto Nazionale dei Tumori in Milan whose international survey with Portenoy characterized the syndromes of cancer pain and who led the European evidence-based recommendations on opioid use. ORCID - Faculty page

Marieke H. J. van den Beuken-van Everdingen (contemporary). Palliative-care researcher at Maastricht University whose systematic reviews and meta-analyses established the definitive estimates of cancer pain prevalence across the disease course. ORCID - Faculty page - Google Scholar

Marie Fallon (contemporary). Chair of palliative medicine at the University of Edinburgh and lead author of the ESMO clinical practice guidelines for the management of cancer pain in adults. ORCID - Faculty page - Google Scholar

Sebastiano Mercadante (contemporary). Palliative-care and pain specialist at La Maddalena Cancer Center in Palermo, a prolific contributor on cancer-pain mechanisms, opioid management, and the nature of breakthrough cancer pain. ORCID - Google Scholar

Judith A. Paice (contemporary). Director of the Cancer Pain Program at Northwestern University's Feinberg School of Medicine and lead author of the ASCO clinical practice guideline on chronic pain in adult cancer survivors. ORCID - Faculty page - Wikidata

Russell K. Portenoy (contemporary). Palliative-care physician at the MJHS Institute for Innovation in Palliative Care and Albert Einstein College of Medicine, a foundational author on cancer-pain syndromes, assessment, and their mechanistic classification. Faculty page - Wikidata

Frequently Asked Questions

What is cancer pain? Cancer pain is pain caused by a malignant tumor invading or compressing tissue, or by the treatments used against it such as surgery, chemotherapy, and radiation. It is usually a mixture of nociceptive pain, from tissue damage, and neuropathic pain, from nerve damage, and most patients report several distinct pains at once (Portenoy, 2011; Caraceni & Portenoy, 1999).

How common is cancer pain? Pain affects roughly half of all cancer patients, rising to about two-thirds of those with advanced, metastatic, or terminal disease, and it is still present in nearly two-fifths of patients after curative treatment. Of those in pain, more than a third rate it as moderate to severe (van den Beuken-van Everdingen et al., 2016).

Why is cancer pain so often undertreated? Because pain can only be reported, not measured directly, treatment depends on patients reporting pain and clinicians acting on it. Fears of opioids and of seeming weak keep pain unspoken, and clinicians underestimate others' pain, so a large minority of patients receive analgesia weaker than their reported pain (Deandrea et al., 2008; Cleeland et al., 1994).

How is cancer pain measured? Because pain is private, it is measured by validated self-report instruments. The most widely used is the Brief Pain Inventory, which rates pain severity on a zero-to-ten scale and, separately, how much pain interferes with mood, activity, sleep, work, and relationships (Cleeland & Ryan, 1994).

Can the mind really change how much cancer pain hurts? Yes. The perceived intensity of an identical noxious signal rises and falls with attention, mood, and appraisal, through identifiable brain circuits that modulate the pain signal. This is why distraction can reduce pain and why catastrophic thinking amplifies it (Bushnell et al., 2013; Melzack & Wall, 1965).

What is pain catastrophizing? Pain catastrophizing is a magnified, ruminative, and helpless orientation toward pain, measured by the Pain Catastrophizing Scale. In cancer patients it predicts worse pain and greater interference over and above the extent of disease, and because it is a cognitive style it can be modified by psychological treatment (Sullivan et al., 1995; Syrjala et al., 2014).

How is cancer pain treated? The pharmacological foundation is the analgesic ladder, matching non-opioid, weak-opioid, and strong-opioid drugs to mild, moderate, and severe pain, with opioid choice and dose refined by titration. Psychological and behavioral methods, such as education, coping-skills and relaxation training, and cognitive restructuring, are effective adjuncts (Ventafridda et al., 1987; Caraceni et al., 2012; Syrjala et al., 2014).

Does cancer pain end when treatment ends? Not always. Many survivors have persistent pain long after the tumor is gone, from surgery, chemotherapy-induced neuropathy, or radiation, and this survivor pain is now addressed by its own clinical guidelines that also weigh the long-term risks of opioid use (Paice et al., 2016; Scarborough & Smith, 2018).

References